154 related articles for article (PubMed ID: 2225567)
1. Immunotherapy of the rat 13762SC mammary adenocarcinoma by vaccinia virus augmentation of tumor immunity.
Archer TP; Bretscher P; Ziola B
Clin Exp Metastasis; 1990; 8(6):519-32. PubMed ID: 2225567
[TBL] [Abstract][Full Text] [Related]
2. Immunotherapy of an established rat mammary adenocarcinoma (13762A) with intratumor injection of Corynebacterium parvum.
Kreider JW; Bartlett GL; Purnell DM; Webb S
Cancer Res; 1978 Mar; 38(3):689-92. PubMed ID: 626972
[TBL] [Abstract][Full Text] [Related]
3. Systemic adoptive transfer of immunity to 13762A rat mammary adenocarcinoma.
Boyer CM; Kreider JW; Bartlett GL
Cancer Res; 1981 Jun; 41(6):2394-400. PubMed ID: 6972251
[TBL] [Abstract][Full Text] [Related]
4. Increased immunogenicity of a spontaneous variant clone of the 13762A rat mammary adenocarcinoma.
Kreider JW; Bartlett GL
J Natl Cancer Inst; 1985 Jul; 75(1):141-9. PubMed ID: 3859687
[TBL] [Abstract][Full Text] [Related]
5. Establishment of tumor-specific immunotherapy model utilizing vaccinia virus-reactive helper T cell activity.
Shimizu Y; Hasumi K; Masubuchi K; Okudaira Y
Eur J Immunol; 1988 Nov; 18(11):1773-8. PubMed ID: 2974424
[TBL] [Abstract][Full Text] [Related]
6. Experimental cancer immunotherapy: comparison of tumor rejection if F344 rats given live Mycobacterium bovis (Strain BCG) and killed Corynebacterium parvum.
Likhite VV
J Natl Cancer Inst; 1976 May; 56(5):985-9. PubMed ID: 994209
[TBL] [Abstract][Full Text] [Related]
7. Rat adenocarcinoma 13762 expresses tumor rejection antigens but tumor-bearing animals exhibit tumor-specific immunosuppression.
Frey AB; Appleman LJ
Clin Immunol Immunopathol; 1993 Nov; 69(2):223-33. PubMed ID: 8403560
[TBL] [Abstract][Full Text] [Related]
8. Immune response to a syngeneic mammary adenocarcinoma. III. Development of memory and suppressor functions modulating cellular cytotoxicity.
Kuperman O; Fortner GW; Lucas ZJ
J Immunol; 1975 Nov; 115(5):1282-7. PubMed ID: 1176776
[TBL] [Abstract][Full Text] [Related]
9. Rejection of tumors and metastases in Fischer 344 rats following intratumor administration of killed Corynebacterium parvum.
Likhite VV
Int J Cancer; 1974 Nov; 14(5):684-90. PubMed ID: 4459281
[No Abstract] [Full Text] [Related]
10. Suitability of rat mammary adenocarcinoma 13762 as a model for BCG immunotherapy.
Kreider JW; Bartlett GL; Purnell DM
J Natl Cancer Inst; 1976 Apr; 56(4):797-802. PubMed ID: 815563
[TBL] [Abstract][Full Text] [Related]
11. Conditions for effective Bacillus Calmette-Guérin immunotherapy of postsurgical metastases of 13762A rat mammary adenocarcinoma.
Kreider JW; Bartlett GL; Boyer CM; Purnell DM
Cancer Res; 1979 Mar; 39(3):987-92. PubMed ID: 427785
[TBL] [Abstract][Full Text] [Related]
12. Induced antitumor immunity against DMBA-4 metastatic mammary tumors in rats using laser immunotherapy.
Chen WR; Jeong SW; Lucroy MD; Wolf RF; Howard EW; Liu H; Nordquist RE
Int J Cancer; 2003 Dec; 107(6):1053-7. PubMed ID: 14601069
[TBL] [Abstract][Full Text] [Related]
13. Systemic adoptive transfer of immunity and low-dose irradiation eradicate metastases of 13762A rat mammary adenocarcinoma.
Kreider JW; Bartlett GL; Christensen ND; Welsh P
Int J Cancer; 1985 Aug; 36(2):217-24. PubMed ID: 3160672
[TBL] [Abstract][Full Text] [Related]
14. Immune response to a syngeneic mammary adenocarcinoma. I. Comparison of kinetics of tumor cell growth and cytotoxic responses in syngeneic and allogeneic rats.
Fortner GW; Kuperman O; Lucas ZJ
J Immunol; 1975 Nov; 115(5):1269-76. PubMed ID: 1080776
[TBL] [Abstract][Full Text] [Related]
15. [Significance of priming of hosts with virus in the tumor-specific immunotherapy model utilizing virus-reactive helper T cell activity].
Shimizu Y; Hasumi K; Masubuchi K; Okudaira Y
Nihon Gan Chiryo Gakkai Shi; 1989 May; 24(5):1007-14. PubMed ID: 2528599
[TBL] [Abstract][Full Text] [Related]
16. Immunotherapy of tumor-bearing mice utilizing virus help.
Shimizu Y; Hasumi K; Masubuchi K; Okudaira Y
Cancer Immunol Immunother; 1988; 27(3):223-7. PubMed ID: 3263207
[TBL] [Abstract][Full Text] [Related]
17. Rejection of mammary adenocarcinoma cell tumors and the prevention of progressive growth of incipient metastases following intratumor permeation with killed Bordetella pertussis.
Likhite VV
Cancer Res; 1974 Oct; 34(10):2790-4. PubMed ID: 4370327
[No Abstract] [Full Text] [Related]
18. Feasibility of UV-inactivated vaccinia virus in the modification of tumor cells for augmentation of their immunogenicity.
Wakamiya N; Wang YL; Imai H; Gu HX; Ueda S; Kato S
Cancer Immunol Immunother; 1986; 23(2):125-9. PubMed ID: 3779714
[TBL] [Abstract][Full Text] [Related]
19. Comparison of immunity in mice cured of primary/metastatic growth of EMT6 or 4THM breast cancer by chemotherapy or immunotherapy.
Gorczynski RM; Chen Z; Erin N; Khatri I; Podnos A
PLoS One; 2014; 9(11):e113597. PubMed ID: 25409195
[TBL] [Abstract][Full Text] [Related]
20. Destruction of regional lymph node metastases of rat mammary adenocarcinoma 13762A by treatment with Corynebacterium parvum.
Kreider JW; Bartlett GL; Purnell DM; Webb S
Cancer Res; 1978 Dec; 38(12):4522-6. PubMed ID: 719637
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
